关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 5 月 31 日（星期三）上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com） 会议召开方式：网络文字互动 证券代码：605388 证券简称：均瑶健康 公告编号：2023-034 湖北均瑶大健康饮品股份有限公司 投资者可于 2023 年 5 月 30 日(星期二)16:00 前登录上证路演中心网站首 页点击"提问预征集"栏目或通过公司邮箱 juneyaodairy@juneyao.com 进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）已于 2023 年 4 月 20 日发布公司 2022 年度报告，于 2023 年 4 月 26 日发布公司 2023 年第一季度 报告，为便于广 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥445,358,945.57, representing a year-on-year increase of 102.84%[5] - Net profit attributable to shareholders was ¥23,916,582.84, reflecting a growth of 30.88% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 35.69%, amounting to ¥18,560,195.20[5] - Basic and diluted earnings per share both rose by 50.00%, reaching ¥0.06 per share[5] - Operating profit for Q1 2023 was ¥33,559,160.01, up 39.5% from ¥24,055,336.49 in the same period last year[23] - Net profit for Q1 2023 was ¥25,089,016.23, representing a 40.3% increase from ¥17,877,917.67 in Q1 2022[24] - The company reported a total comprehensive income of ¥25,089,016.23 for Q1 2023, compared to ¥17,877,917.67 in Q1 2022, indicating a growth of 40.3%[24] Cash Flow and Assets - The company reported a net cash flow from operating activities of -¥92,212,326.92, indicating a significant cash outflow[5] - As of March 31, 2023, the company's cash and cash equivalents decreased to ¥350,039,060.41 from ¥679,573,145.89 as of December 31, 2022, representing a decline of approximately 48.7%[18] - The company's total current assets decreased to ¥1,074,184,524.79 from ¥1,275,853,913.67, a reduction of about 15.7%[19] - The company's inventory decreased to ¥165,470,212.87 from ¥172,441,648.85, reflecting a decline of approximately 4.0%[19] - The company's total liability was ¥336,105,983.23 as of March 31, 2023, down from ¥463,581,613.79, indicating a decrease of approximately 27.4%[20] - The company's non-current assets increased to ¥1,198,002,162.87 from ¥1,113,428,881.49, showing an increase of about 7.6%[19] Market and Growth Strategies - The growth in revenue is attributed to increased consumer demand due to economic recovery, proprietary technology, new products, and online channels[9] - The company has implemented cost reduction and efficiency improvement measures, contributing to the increase in profitability[9] - The company reported significant growth in key operating metrics for the first quarter of 2023, benefiting from increased consumer demand and reduced raw material costs[14] - The lactobacillus business has resumed growth, with product upgrades enhancing core competitiveness, including the introduction of patented health function strains[14] - The company has signed a strategic cooperation agreement with Jiangnan University to develop new strains related to gastrointestinal health, aiming to enrich its product matrix[14] - The company plans to expand its distribution channels to cover town-level markets, enhancing its market presence in lower-tier cities[14] - The restructuring of Junyao Runying Biotechnology (Shanghai) Co., Ltd. has been successfully completed, opening up a second growth curve for probiotics[15] - The company aims to establish a differentiated segment in the lactobacillus market focused on "gut health," leveraging technological patents to maintain industry leadership[14] - The company is focused on enhancing its brand loyalty and meeting consumer needs through innovative product offerings[14] - The overall market sentiment is improving, with a recovery in consumer confidence contributing to the company's positive performance outlook[14] - The company achieved significant breakthroughs in product development, launching new products that received positive market feedback and securing major contracts, laying a solid foundation for annual revenue targets[16] - The company aims to enhance its probiotic brand matrix and expand market influence through improved product offerings and channel strategies[16] - The company plans to leverage its partnership with Junyao Runying to maximize synergy across the entire supply chain of probiotics, enhancing overall operational efficiency[16] Costs and Expenses - Total operating costs for Q1 2023 were ¥419,222,497.70, an increase of 109.3% from ¥199,906,434.66 in Q1 2022[22] - Research and development expenses for Q1 2023 were ¥3,876,444.20, a decrease of 24.2% compared to ¥5,113,114.70 in Q1 2022[22] - The company has implemented cost control measures, optimizing expense allocation to improve efficiency[14] - The company has adjusted the ex-factory prices of some products due to the recent upgrades and inflationary pressures on raw materials[14]

Financial Performance - In 2022, the company achieved a net profit attributable to all shareholders of RMB 76,631,268.40, with a total distributable profit of RMB 418,893,647.68 at the end of the reporting period[5]. - The company's operating revenue for 2022 was CNY 986,104,247.74, representing a year-on-year increase of 7.94% compared to CNY 913,598,918.70 in 2021[26]. - The net profit attributable to shareholders for 2022 was CNY 76,631,268.40, a decrease of 47.87% from CNY 146,987,705.81 in 2021[26]. - The basic earnings per share for 2022 was CNY 0.18, down 47.06% from CNY 0.34 in 2021[28]. - The cash flow from operating activities for 2022 was CNY 179,878,265.00, a significant decrease compared to CNY 81,721,356.48 in 2021, reflecting a decline of 258.10%[26]. - The company's net assets attributable to shareholders at the end of 2022 were CNY 1,921,191,424.25, a slight decrease of 0.93% from CNY 1,930,840,672.63 at the end of 2021[26]. - The weighted average return on equity for 2022 was 3.99%, down from 7.33% in 2021, a decrease of 3.34 percentage points[28]. - The company reported a significant increase in costs due to higher raw material prices and increased investment in probiotic products, impacting net profit[29]. - The fourth quarter of 2022 saw a net profit of CNY -2,279,853.50, contrasting with profits in the previous three quarters[31]. Dividend Policy - The proposed cash dividend for 2022 is RMB 1.00 per 10 shares (including tax), amounting to a total of RMB 43,000,000 (including tax), resulting in a cash dividend payout ratio of 56.11%[5]. - The company maintains a stable dividend distribution policy to protect investors' legitimate rights and interests[5]. Market and Product Development - The company plans to continue focusing on product development and market expansion to improve future performance[29]. - The company's probiotic business achieved sales revenue exceeding 80 million yuan, representing a year-on-year growth of 43%[41]. - The new product "Post-meal Light Body" became the second product after "Taste Power 330" to exceed 100 million yuan in sales, indicating strong growth potential[41]. - The company launched 72 new SKUs in the probiotic product line, transitioning from a steady pace to a "small steps, quick runs" approach in product innovation[42]. - The number of new retail channels, including urban CVS and vending machines, increased by 11,000 by the end of 2022, enhancing market coverage[41]. - The company's e-commerce sales grew by 46%, with 18 official stores established across various platforms including Tmall and JD[42]. Strategic Initiatives - The company signed strategic cooperation agreements with universities to enhance its innovation capabilities in the health industry[42]. - The company established a "Probiotics & Postbiotics Health Functional Food Innovation Center" in collaboration with Northeast Agricultural University and Shanghai University of Science and Technology to promote sustainable development in the health food industry[43]. - The acquisition of Junyao Runying, a leading domestic probiotics manufacturer, added over 30 local probiotic strains and a resource library of more than 4,000 proprietary strains, enhancing the company's industry position[43]. - The company aims to develop Junyao Runying into the largest and most competitive probiotics raw material leader in China within three years, leveraging its core capabilities in the Shanghai market[44]. Operational Efficiency - The company operates its own factories in Yichang, Hubei, and Quzhou, Zhejiang, but faces capacity constraints that limit production during peak seasons[52]. - The company utilizes a contract manufacturing model to supplement its production capacity, ensuring a steady supply of products to meet market demand[52]. - The company has established a comprehensive sales network focused on second- and third-tier cities, developing a single distributor per region to enhance marketing efficiency[53]. - The company has invested significantly in R&D to improve production processes and ensure the stability and advancement of its technology[55]. - The company has formed an integrated supply chain for probiotics, covering raw material production to end-product manufacturing, enhancing its competitive edge in the market[55]. Risk Management - There are no significant risks that materially affect the company's production and operations during the reporting period[9]. - The company has not experienced any non-operational fund occupation by controlling shareholders or related parties[8]. - The company acknowledges risks from intensified market competition and fluctuating raw material prices, particularly in the probiotic beverage sector[133]. - The company has established a comprehensive quality control system covering procurement, production, storage, distribution, and sales to address food safety risks[134]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present at the board meeting[8]. - The company has committed to strict compliance with the regulatory requirements and will submit a rectification report within the specified timeframe[157]. - The company has implemented a robust internal control system, with no significant deficiencies reported during the evaluation period[183]. - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management, linking operational indicators to annual business goals[182]. Social Responsibility - The company has committed to social responsibility by donating 60 million yuan worth of probiotic drinks to support disaster relief efforts[189]. - The company has established a long-term poverty alleviation mechanism through employment and development initiatives, benefiting local communities[190].

Financial Performance - The company's revenue for Q3 2022 reached ¥303,971,479.03, representing a year-on-year increase of 35.99%[5] - Net profit attributable to shareholders for Q3 2022 was ¥33,489,385.99, a significant increase of 71.55% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥28,138,724.03, up 82.06% year-on-year[5] - Year-to-date revenue as of Q3 2022 totaled ¥844,841,561.52, reflecting a 20.62% increase compared to the same period last year[5] - Year-to-date net profit attributable to shareholders decreased by 45.21% to ¥78,911,121.91 due to increased costs and pandemic-related disruptions[5][10] - The basic earnings per share for Q3 2022 was ¥0.08, a decrease of 45.45% year-to-date[6][10] - The net profit for Q3 2022 was CNY 78,433,591.54, a decrease of 45% compared to CNY 142,829,123.17 in Q3 2021[26] - The total profit for Q3 2022 was CNY 98,292,856.77, down 48.9% from CNY 192,694,704.70 in the same period last year[26] - The basic and diluted earnings per share for Q3 2022 were both CNY 0.18, compared to CNY 0.33 in Q3 2021, reflecting a decline of 45.5%[28] Cash Flow and Assets - The company reported a significant cash flow deficit from operating activities of -¥297,731,355.85 for the year-to-date period[6] - The company's cash and cash equivalents decreased to CNY 586,225,646.10 as of September 30, 2022, down 45.6% from CNY 1,077,382,405.31 at the end of 2021[20] - Cash and cash equivalents at the end of Q3 2022 were CNY 571,768,192.77, down from CNY 1,200,136,754.39 at the end of Q3 2021[31] - The total assets as of the end of Q3 2022 were ¥2,151,818,462.32, down 6.30% from the end of the previous year[6] - The total assets of the company as of September 30, 2022, were CNY 2,151,818,462.32, a decrease of 6.3% from CNY 2,296,495,401.64 at the end of 2021[22] - The total liabilities decreased to CNY 221,152,428.47 as of September 30, 2022, down 36.7% from CNY 349,662,959.33 at the end of 2021[22] Operational Challenges and Strategies - The company attributed the decline in net profit to increased R&D investments and rising raw material costs, along with pandemic-related operational challenges[10] - The company has implemented cost reduction and efficiency enhancement strategies to counteract rising raw material prices, optimizing its cost structure[14] - The company is focusing on new product development and channel expansion to drive future growth[10] - The company aims to enhance digital capabilities to support operational visualization and precision marketing, focusing on integrating online and offline customer experiences[18] Product Development and Market Strategy - The "Weidongli" ambient yogurt beverage business achieved both quarter-on-quarter and year-on-year revenue growth in Q3 2022[14] - The functional probiotic product matrix has been enriched, establishing initial product barriers for long-term strategic implementation[14] - New probiotic products, including the "Qingyou" and "Changyin" series, have shown significant growth, with the "Xianmeijun" series launched in the second half of the year[15] - The company is focusing on a dual-channel strategy to expand its market presence among first and second-tier consumers and new retail channels[17] - The company aims to become a globally competitive enterprise in the probiotic industry through strategic partnerships and supply chain integration[16] Research and Development - Research and development expenses for the first three quarters of 2022 were CNY 13,705,502.95, significantly higher than CNY 5,910,809.38 in the same period of 2021, reflecting a growth of 132.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,488[12] - The largest shareholder, Shanghai Junyao Group, holds 32.66% of shares, with 140,451,430 shares pledged[12]

2022 年半年度报告 公司代码：605388 公司简称：均瑶健康 湖北均瑶大健康饮品股份有限公司 2022 年半年度报告 1 / 156 2022 年半年度报告 重要提示 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用□不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内，公司不存在对生产经营产生实质性影响的特别重大风险。公司已在本报告第三节 "管理层讨论与分析"等有关章节详细描述了公司可能面临的风险，敬请投资者予以关注。 十一、 其他 □适用√不适用 2 / 156 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三 ...

2022 年第一季度报告 证券代码：605388 证券简称：均瑶健康 湖北均瑶大健康饮品股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2022 年第一季度报告 | 加权平均净资产收益率（%） | | 0.94 | 减少 | 2.34 | 个百分点 | | --- | --- | --- | --- | --- | --- | | | 本报告期末 | 上年度末 | 本报告期末比上年度末 增减变动幅度(%) | | | | 总资产 | 2,202,817,227.82 | 2,296,495,401.64 | | | -4.08 | | 归属于上市公司股东的 | 1,957,433,676.90 | 1,939,160,155.85 | | | 0.94 | | 所有者权益 | | | | | | 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负 ...

2021 年年度报告 公司代码：605388 公司简称：均瑶健康 湖北均瑶大健康饮品股份有限公司 2021 年年度报告 1 / 226 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 大华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人王均豪、主管会计工作负责人朱航明及会计机构负责人（会计主管人员）崔鹏声 明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2021年实现归属于全体股东的净利润为146,987,705.81元，报告期末公司可 供分配利润为394,067,242.35元。经综合考虑公司所处行业特点、现处发展阶段及盈 利水平，推动并实施持续、稳定的股利分配政策，保护投资者合法权益，经审慎研究， 结合公司经营情况和整体财务状况，公司2021年度拟以实施权益分派股权登记日登记 的总股本为基数分配利润。公司2021年 ...

2021 年第三季度报告 证券代码：605388 证券简称：均瑶健康 湖北均瑶大健康饮品股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是√否 (二)非经常性损益项目和金额 单位：元 币种：人民币 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 223,521,453.78 | ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 476,878,408.30, a decrease of 4.46% compared to CNY 499,144,455.02 in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2021 was CNY 124,491,326.23, down 16.45% from CNY 149,003,499.05 in the previous year[18]. - Basic earnings per share for the first half of 2021 were CNY 0.29, down 29.27% from CNY 0.41 in the same period last year[20]. - The company reported a decrease of 26.51% in net profit after deducting non-recurring gains and losses, amounting to CNY 88,905,079.80 compared to CNY 120,980,277.01 in the previous year[18]. - The company achieved a revenue of RMB 476,878,408.30 and a net profit of RMB 124,491,326.23 during the reporting period[42]. - The company reported a total profit of RMB 59,414,296.86 for the first half of 2021, compared to RMB 57,304,040.08 in the same period of 2020, indicating a growth of 3.7%[145]. - The company’s total comprehensive income for the first half of 2021 was RMB 43,272,518.61, slightly higher than RMB 42,977,630.26 in the first half of 2020[146]. Cash Flow and Investments - The net cash flow from operating activities increased significantly to CNY 77,351,630.15, a 391.67% increase compared to CNY 15,732,316.90 in the same period last year[18]. - The company recorded a net cash inflow from investment activities of RMB 94,212,080.10, contrasting with a net outflow of RMB 17,684,657.61 in the first half of 2020[148]. - The company’s cash flow from financing activities was primarily impacted by dividend distributions amounting to 137,600,000.00 RMB[155]. - The company received 500,000,000.00 RMB from the recovery of investments during the first half of 2021, indicating strong investment management[150]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,225,019,132.51, reflecting a 2.45% increase from CNY 2,171,712,744.37 at the end of the previous year[19]. - Cash and cash equivalents at the end of the period amounted to ¥1,052,967,138.05, representing 47.32% of total assets, a slight increase of 2.05% compared to the previous year[61]. - Total liabilities amounted to CNY 299,994,866.10, compared to CNY 240,457,402.13, reflecting an increase of approximately 24.7%[134]. - The company's total assets decreased to CNY 1,723,911,957.26 from CNY 1,941,379,041.38 at the end of the previous period[138]. Research and Development - The company has invested significantly in R&D to enhance its production technology and ensure the stability and advancement of its processes[32]. - The company increased R&D investment by 340.22% year-on-year, totaling RMB 3,364,516.72, and added 3 new R&D personnel[43]. - Research and development expenses surged by 340.22% to ¥3.36 million, reflecting increased investment in R&D personnel and external collaborations[58]. - The company is focusing on innovation and product development, aiming to lead in the probiotics market and expand into new product categories[41]. Market Strategy and Operations - The company operates in the "Manufacturing of Dairy, Beverages, and Refined Tea" industry, specifically in the "Manufacturing of Dairy Beverages and Plant Protein Beverages" sector[24]. - The sales model primarily relies on a distribution strategy, targeting second and third-tier cities and expanding into county markets[30]. - The company has established a strong brand presence in the ambient yogurt market, with a competitive market share among first-tier brands[25]. - The company aims to gradually increase its self-owned production capacity to overcome existing scale bottlenecks[29]. Risks and Challenges - The company faces risks from intensified market competition in the ambient yogurt drink sector, which has seen rapid growth and high profit margins, attracting numerous brands[72]. - Raw material price fluctuations pose a significant risk, as key materials like skimmed milk powder and PE particles constitute a large portion of production costs, potentially impacting gross margins and profitability[72]. - The ongoing uncertainty from the COVID-19 pandemic continues to impact the supply chain, raw material prices, and consumer demand, leading to potential fluctuations in operational performance[72]. Corporate Governance and Compliance - The company has not faced any administrative penalties related to environmental issues and adheres to national environmental protection laws[80]. - The company has not disclosed any significant updates regarding its employee incentive plans or stock options during the reporting period[78]. - The company will comply with all relevant laws and regulations regarding share transfers and will accept supervision from regulatory bodies and investors[90]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 23,711[120]. - The top ten shareholders hold a total of 140,451,430 shares, representing 32.66% of the total shares outstanding[122]. - Wang Junjin, the actual controller of Shanghai Junyao Group, holds 103,995,000 shares, accounting for 24.18%[122]. Future Outlook - The company plans to launch a new dietary fiber-rich fresh fruit milk product in the second half of 2021 to expand its neutral milk beverage offerings[49]. - The company aims to enhance its online operations and product offerings, with a focus on private traffic operations and live streaming sales[51]. - The company will actively pursue capital operations to support its core business development and achieve exponential growth[55].

2020 年年度报告 公司代码：605388 公司简称：均瑶健康 湖北均瑶大健康饮品股份有限公司 2020 年年度报告 （更新版） 1 / 187 2020 年年度报告 重要提示 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司2020年实现归属于全体股东的净利润为213,834,514.97元，报告期末公司可供分配利润为 400,864,221.03元。经综合考虑公司所处行业特点、现处发展阶段及盈利水平，推动并实施持续、 稳定的股利分配政策，保护投资者合法权益，经审慎研究，我们拟订了2020年度公司利润分配预 案：向全体股东进行现金股利分配，每10股派发现金红利3.2元（含税），以截至2020年12月31日 公司总股本43,000.00万股为基数计算，共计派发13,760.00万元（含税）；2020年度公司不进行资本 公积金转增股本。 六、 前瞻性陈述的风险声明 √适用□不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请投资 者注意投资风险。 2 / 187 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提 ...